摘要
基础理论:2009年出现的一种新的基因重组H1N1病毒导致了21世纪的第一次流感大流行。目前可用于流感治疗的方法已有耐药性。因此,有必要开发新一代的免疫治疗抗病毒策略。本研究描述了一种新型双功能免疫刺激的siRNA,通过靶向核衣壳蛋白(NP)基因对H1N1猪流感病毒的治疗功效。方法和结果:小干扰RNA(siRNA)针对NP保守区域筛选人肺上皮细胞(A549)抗病毒疗效。此外,通过用NP特异性siRNA结合免疫刺激序列(5’-UGUGU-3’),合成了一种双功能siRNA。此免疫刺激的siRNA(NP-1-is)通过mRNA拷贝数减少(99.58%)说明了强烈的抗病毒作用,病毒相关细胞凋亡及Western blot中核衣壳蛋白抑制的减少。发现此免疫刺激的siRNA比非标记的siRNA更有效。包括剂量依赖性和时间过程的进一步动力学研究表明,NP-1-is siRNA在20-80 nM范围内是更有效的,有显著保护作用并达到48 hpi的。另外,通过实时荧光定量PCR和Western blot分析证实siRNA高免疫抗病毒反应是由于对TLR-7 MyD88、IRF-7和IFN-α表达上调引起的。结论:本研究奠定了使用广谱免疫刺激提高RNAi抗病毒疗法的基础。因此,在对抗流行株的突然出现时本方法是有用的。
关键词: 抗病毒活性,双功能siRNA,小干扰RNA(siRNA),猪流感(H1N1)病毒。
Current Gene Therapy
Title:Bifunctional siRNA Containing Immunostimulatory Motif Enhances Protection Against Pandemic H1N1 Virus Infection
Volume: 15 Issue: 5
Author(s): Gaurav Joshi, Paban Kumar Dash, Ankita Agarwal, Shashi Sharma and Manmohan Parida
Affiliation:
关键词: 抗病毒活性,双功能siRNA,小干扰RNA(siRNA),猪流感(H1N1)病毒。
摘要: Rationale: The first influenza pandemic of 21st century was attributed to a novel quadruple reassortant H1N1 virus that emerged in 2009. Currently available therapies for influenza have drugresistant. Therefore, there is a need to develop new generation immunotherapeutic antiviral strategy. This study described the efficacy of a novel bifunctional immunostimulatory siRNAs against H1N1pdm swine flu virus by targeting the Nucleocapsid (NP) gene. Methods & Findings: Small interfering RNAs (siRNA) targeting conserved region of NP were screened for antiviral efficacy in human lung epithelial cells (A549). Further, a bifunctional siRNA was synthesized by combining immunostimulatory sequence (5’-UGUGU-3’) with NP specific siRNA. This immunostimulatory siRNA (NP-1-is) revealed strong antiviral effect through reduction in mRNA copies (99.58%), reduction in virus associated cell apoptosis and inhibition of nucleocapsid protein in western blot. This immunostimulatory siRNA was found more effective than nontagged siRNA. Further studies including dose dependent and time course kinetics revealed that the NP-1-is siRNA is more effective at 20-80 nM with significant protection upto 48 hpi. Besides, the qRT-PCR and western blot analysis confirmed higher antiviral response of immunostimulatory siRNA was due to upregulation of TLR-7 MyD88, IRF-7 and IFN-α. Conclusions: This study paves the way for broad-spectrum RNAi-based therapeutics using immunostimulatory motif towards improved antiviral effect. Hence this approach will be useful to confront the sudden emergence of pandemic strains.
Export Options
About this article
Cite this article as:
Joshi Gaurav, Kumar Dash Paban, Agarwal Ankita, Sharma Shashi and Parida Manmohan, Bifunctional siRNA Containing Immunostimulatory Motif Enhances Protection Against Pandemic H1N1 Virus Infection, Current Gene Therapy 2015; 15 (5) . https://dx.doi.org/10.2174/1566523215666150812120547
DOI https://dx.doi.org/10.2174/1566523215666150812120547 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery The Yin and Yang of microRNA Assay Methods
MicroRNA TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy Integrins in Bone Metastasis Formation and Potential Therapeutic Implications
Current Cancer Drug Targets Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Pharmacological Approaches to Targeting Muscarinic Acetylcholine Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets New Therapies for Patients with Chronic Lymphocytic Leukemia
Current Cancer Therapy Reviews Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology Cigarette Smoke-Induced Proteostasis Imbalance in Obstructive Lung Diseases
Current Molecular Medicine Synthetic Lethal Interactions in Cancer Therapy
Current Cancer Drug Targets Known Triterpenes and their Derivatives as Scaffolds for the Development of New Therapeutic Agents for Cancer
Current Medicinal Chemistry Design, Synthesis and Pharmacological Evalution of 1,3,4-Oxadiazole Derivatives as Collapsin Response Mediator Protein 1 (CRMP 1) Inhibitors
Current Drug Discovery Technologies Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Stem Cell Differentiation Stage Factors and their Role in Triggering Symmetry Breaking Processes during Cancer Development: A Quantum Field Theory Model for Reprogramming Cancer Cells to Healthy Phenotypes
Current Medicinal Chemistry